Influence of alpha1-adrenoblockers on the ejaculatory function of patients with benign prostatic hyperplasia

Abstract

BACKGROUND: The cause of ejaculatory dysfunction in patients with benign prostatic hyperplasia can be either the disease itself or its surgical or drug treatment, including the use of alpha1-blockers.

AIM: To study the effect of alpha1-blockers on the ejaculatory function of patients with benign prostatic hyperplasia.

MATERIALS AND METHODS: Under observation were 90 patients with benign prostatic hyperplasia aged from 56 to 79 years, who were distributed into 3 groups of 30 people. Patients of the group 1 were prescribed tamsulosin at a dose of 0.4 mg once a day, patients of the group 2 were prescribed silodosin at a dose of 8 mg once a day, and patients of the group 3 were prescribed alfuzosin 10 mg once a day. Duration of treatment is 4 weeks. To assess the effectiveness of treatment and its impact on copulatory function before and after treatment, patients filled out the IPSS, IIEF-5, ICF and MSHQ questionnaires.

RESULTS: The reduction in the severity of clinical manifestations of benign prostatic hyperplasia and the improvement in quality of life in patients of the three groups were the same. The effect of alpha1-blockers on erectile function has not been noted. A significant decrease in ejaculatory function was revealed in patients of the groups 1 and 2, while in patients of the group 3 no changes in ejaculatory function were observed.

CONCLUSIONS: When planning drug therapy for patients with benign prostatic hyperplasia, it is necessary to take into account the specific effects of different alpha1-blockers on ejaculatory function.

Keywords

benign prostatic hyperplasia / conservative therapy / ejaculatory function / tamsulosin / silodosin / alfuzosin.

References

[1] Apolihin OI, Komarova VA, Nikushina AA, Sivkov AV. Prostate diseases in the Russian Federation: statistical data for 2008–2017. Experimental and clinical urology. 2019;(2):4–13. EDN: DHXMJP doi: 10.29188/2222-8543-2019-11-2-4-12

[2] Аполихин О.И., Сивков А.В., Комарова В.А., Никушина А.А. Болезни предстательной железы в Российской Федерации: статистические данные 2008–2017 гг. // Клиническая и экспериментальная урология. 2019. № 2. С. 4–13. EDN: DHXMJP doi: 10.29188/2222-8543-2019-11-2-4-12

[3] LLC “Russian Society of Urologists”. Clinical Recommendations of the Ministry of Health of the Russian Federation “Benign prostatic hyperplasia”, 2020. Available from: https://cr.minzdrav.gov.ru/schema/6_1?ysclid=lukv36kwbm720871222 (In Russ.)

[4] ООО «Российское общество урологов». Клинические рекомендации Минздрава РФ «Доброкачественная гиперплазия предстательной железы», 2020. Режим доступа: https://cr.minzdrav.gov.ru/schema/6_1?ysclid=lukv36kwbm720871222

[5] Lukianov IV, Kotov SV. Drug therapy for benign prostatic hyperplasia and sexual dysfunction. The clinician. 2006;1(3):40–46. EDN: LPBAWF

[6] Лукьянов И.В., Котов С.В. Медикаментозная терапия доброкачественной гиперплазии предстательной железы и сексуальная дисфункция // Клиницист. 2006. Т. 1, № 3. С. 40–46. EDN: LPBAWF

[7] Glybochko PV, Alyaev YG, Chaly ME, et al. Sexual disorders in men. Moscow: GEOTAR-Media, 2012. 112 p. (In Russ.)

[8] Глыбочко П.В., Аляев Ю.Г., Чалый М.Е., и др. Половые расстройства у мужчин. Москва: ГЭОТАР-Медиа, 2012. 112 с.

[9] Korshunov MN, Korshunova ES, Darenkov SP. Retarded ejaculation. Etiology, diagnosis, therapy. Reproductive aspects of the problem. Kremlin Medicine Journal. 2017;(2):79–85. EDN: YPIFJN

[10] Коршунов М.Н., Коршунова Е.С., Даренков С.П. Отсроченная эякуляция. Этиология, диагностика, лечение. Репродуктивные аспекты проблемы // Кремлевская медицина. Клинический вестник. 2017. № 2. С. 79–85. EDN: YPIFJN

[11] Tyuzikov IA. Ejaculatory dysfunctions in men as a modern interdisciplinary medical and social problem. Medical alphabet. 2014;3(16):19–24. EDN: STHDTD

[12] Тюзиков И.А. Эякуляторные дисфункции у мужчин как современная междисциплинарная медико-социальная проблема // Медицинский алфавит. 2014. Т. 3, № 16. С. 19–24. EDN: STHDTD

[13] Kholodniy VA. Symptomatic sexual dysfunctions in urological practice. Experimental and clinical urology. 2013;(4):58–65. EDN: RVFGFZ

[14] Холодный В.А. Симптоматические сексуальные дисфункции в урологической практике // Экспериментальная и клиническая урология. 2013. № 4. С. 58–65. EDN: RVFGFZ

[15] Al-Shukri SKh, Zhuravlev VN, Kogan MI, et al. A study of sexual function of patients with benign prostatic hyperplasia during treatment with alfuzosin. RMJ. 2008;16(29):1997–2001. EDN: TIMAOB

[16] Аль-Шукри С.Х., Журавлев В.Н., Коган М.И., и др. Исследование сексуальной функции пациентов с доброкачественной гиперплазией предстательной железы при лечении альфузозином // РМЖ. 2008. Т. 16, № 29. С. 1997–2001. EDN: TIMAOB

[17] Capogrosso P, Serino A, Ventimiglia E, et al. Effects of silodosin on sexual function — realistic picture from the everyday clinical practice. Andrology. 2015;3(6):1076–1081. doi: 10.1111/andr.1209

[18] Capogrosso P., Serino A., Ventimiglia E., et al. Effects of silodosin on sexual function — realistic picture from the everyday clinical practice // Andrology. 2015. Vol. 3, N. 6. P. 1076–1081. doi: 10.1111/andr.1209

[19] Pushkar DYu, Rasner PI. Lower urinary tract symptoms and benign prostatic hyperplasia. Urologiia. 2018;(S1):30–45. EDN: YLVSNN

[20] Пушкарь Д.Ю., Раснер П.И. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы // Урология. 2018. № S1. С. 30–45. EDN: YLVSNN

[21] Tang D-D, Li C, Peng D-W, Zhang X-S. Validity of premature ejaculation diagnostic tool and its association with International Index of Erectile Function-15 in Chinese men with evidence-based-defined premature ejaculation. Asian J Androl. 2018;20(1):19–23. doi: 10.4103/aja.aja_9_17

[22] Tang D.-D., Li C., Peng D.-W., Zhang X.-S. Validity of premature ejaculation diagnostic tool and its association with International Index of Erectile Function-15 in Chinese men with evidence-based-defined premature ejaculation // Asian J Androl. 2018. Vol. 20, N. 1. P. 19–23. doi: 10.4103/aja.aja_9_17

[23] Rosen RC, Catania JA, Althof SE, et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology. 2007;69(5):805–809. doi: 10.1016/j.urology.2007.02.036

[24] Rosen R.C., Catania J.A., Althof S.E., et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction // Urology. 2007. Vol. 69, N. 5. P. 805–809. doi: 10.1016/j.urology.2007.02.036

[25] Zhang X, Tang D, Xu C, et al. The relationship between self-estimated intravaginal ejaculatory latency time and International Prostate Symptom Score in middle-aged men complaining of ejaculating prematurely in China. J Sex Med. 2015;12(3):705–712. doi: 10.1111/jsm.12811

[26] Zhang X., Tang D., Xu C., et al. The relationship between self-estimated intravaginal ejaculatory latency time and International Prostate Symptom Score in middle-aged men complaining of ejaculating prematurely in China // J Sex Med. 2015. Vol. 12, N. 3. P. 705–712. doi: 10.1111/jsm.12811

[27] Martov AG, Dukhanin AS, Bernikov AN. Current issues in alpha1-adrenergic blocker therapy: integration of pharmacological approach and clinical experience. Urologiia. 2022;(3):166–175. EDN: IJAQZM doi: 10.18565/urology.2022.3.166-175

[28] Мартов А.Г., Духанин А.С., Берников А.Н. Актуальные вопросы терапии альфа1-адреноблокаторами: интеграция фармакологического подхода и клинического опыта // Урология. 2022. № 3. С. 166–175. EDN: IJAQZM doi: 10.18565/urology.2022.3.166-175

RIGHTS & PERMISSIONS

Eco-Vector